AME 527
Latest Information Update: 26 Mar 2009
At a glance
- Originator Applied Molecular Evolution
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 24 Nov 2005 Phase-I/II clinical trials in Rheumatoid arthritis in USA (unspecified route)
- 24 Nov 2005 Data presented at the 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2005) have been added to the adverse events and Rheumatic disease pharmacodynamics sections
- 16 Feb 2004 Applied Molecular Evolution has been acquired by Eli Lilly